Cargando…
Targeted introduction and effective expression of hFIX at the AAVS1 locus in mesenchymal stem cells
Hemophilia B occurs due to a deficiency in human blood coagulation factor IX (hFIX). Currently, no effective treatment for hemophilia B has been identified, and gene therapy has been considered the most appropriate treatment. Mesenchymal stem cells (MSCs) have homing abilities and low immunogenicity...
Autores principales: | Li, Shu-Jun, Luo, Ying, Zhang, Le-Meng, Yang, Wei, Zhang, Guo-Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367337/ https://www.ncbi.nlm.nih.gov/pubmed/28112377 http://dx.doi.org/10.3892/mmr.2017.6131 |
Ejemplares similares
-
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs
por: Majowicz, Anna, et al.
Publicado: (2019) -
Role of antigen-specific regulatory CD4(+)CD25(+) T cells in tolerance induction after neonatal IP administration of AAV-hF.IX
por: Shi, Y, et al.
Publicado: (2013) -
Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors
por: Ramachandra, Chrishan J. A., et al.
Publicado: (2011) -
Nonviral Gene Targeting at rDNA Locus of Human Mesenchymal Stem Cells
por: Hu, Youjin, et al.
Publicado: (2013) -
CRISPR/Cas9-AAV Mediated Knock-in at NRL Locus in Human Embryonic Stem Cells
por: Ge, Xianglian, et al.
Publicado: (2016)